PDC*line Pharma has been selected for an oral presentation at the “Educational Days” of the Francophone Society of Histocompatibility and Immunogenetics (SFHI)

We are thrilled to announce that we have been selected for an oral presentation at the “Educational Days” of the Francophone Society of Histocompatibility and Immunogenetics (SFHI), held in Strasbourg from October 9 to 11, 2024!
The presentation, delivered Thursday, October 10th by Séverine PLANEL, was titled: "Study of the humoral response of cancer patients (DSA) to a cellular vaccine based on an allogenic plasmacytoid dendritic cell line, in combination or not with anti-PD1 treatment."

Following our presentations at the annual conferences of AACR, CIMT, EFI, and the 50th Annual Meeting of the Korean Cancer Association (KCA 2024), this is our fifth oral presentation of clinical results at an international and prestigious medical/scientific conference this year!

Learn more about the event: https://lnkd.in/gz5SQndR

About the SFHI

The mission of the SFHI is to strengthen the cohesion and increase the Histocompatibility and Immunogenetics community.

The SFHI aims to develop and disseminate medical and scientific knowledge and applications in Histocompatibility and Immunogenetics.
The SFHI organizes, supports and encourages:
- symposia, courses, conferences, webinars, congresses, publications and all forms of teaching, research and training on the above-mentioned themes,
- the awarding of scholarships, prizes and rewards, proposed by the scientific council and validated by the board of directors (CA),
- close relationships with other national and international learned societies,
- the promotion of organ or cell donation in conjunction with public authorities,
- relations with supervisory authorities.
It supports public French-speaking Histocompatibility and Immunogenetics laboratories or those participating in the public service.